Polycythemia Vera clinical trials

Explore recruiting polycythemia vera clinical trials.

Recruiting polycythemia vera studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polycythemia Vera trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera

Bulgaria, Poland, Germany, Italy, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera

Spain, Portugal, Belgium, Netherlands, Germany, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy Study.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM

Germany

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Atorvastatinbehandling til patienter med de Philadelphia-negative kronisk myeloproliferative neoplasier - essentiel trombocytose, polycythemia vera og præfibrotisk myelofibrose.

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Polycythemia Vera trials by city

Polycythemia Vera in Toronto Polycythemia Vera in Vancouver Polycythemia Vera in Montreal Polycythemia Vera in Calgary Polycythemia Vera in Edmonton Polycythemia Vera in Ottawa Polycythemia Vera in Winnipeg Polycythemia Vera in Quebec City Polycythemia Vera in Hamilton Polycythemia Vera in Kitchener Polycythemia Vera in London Polycythemia Vera in Halifax Polycythemia Vera in New York Polycythemia Vera in Los Angeles Polycythemia Vera in Chicago Polycythemia Vera in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease